Retrieved from Tabrizi, R., Saneei, P., Lankarani, K
In an interview with Fierce Pharma, Lange also discussed that while retatrutide may have led to greater weight loss than CagriSema in recent studies, given plans for further late-stage CagriSema trials, the "jury is still out." Yet while Lange's remarks suggest Novo Nordisk could be a comeback kid among pharmaceutical stocks, investors may wait until sales growth data begins to back up these claims
For example, a provider can order a compounded formulation for a patient allergic to an ingredient (such as dyes or preservatives) in the commercial product
I am so thankful I found this
Regulatory review for additional oral GLP-1 options is anticipated in the coming years, potentially as early as 2026
Mounjaro is a breakthrough medicine for medical weight loss, helping many people achieve significant results